CLOSE
MENU
A female doctor explains a procedure to a patient
A female doctor explains a procedure to a patient

GLAUCOMA

Explore our product portfolio.

Please refer to Summary of Product Characteristics before prescribing. Further information about this product can be requested from the Marketing Authorisation Holder or may be found in the Summary of Product Characteristics.

Vizilatan Duo 50μg/ml of latanoprost + 5 mg/ml of timolol product shot
Vizilatan Duo 50μg/ml of latanoprost + 5 mg/ml of timolol product shot

Vizilatan Duo 50 micrograms/mL + 5 mg/mL eye drops, solution (Preservative Free)

(50μg/ml of latanoprost + 5 mg/ml of timolol)

Composition:

Each mL of solution contains 50 micrograms of latanoprost and 5 mg of timolol (as 6.8 mg of timolol maleate). One drop of solution contains approximately 1.5 micrograms of latanoprost and 0.15 mg of timolol (as 0.204 mg of timolol maleate).

Indication:

Vizilatan Duo is indicated in adults (including the elderly) for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.

Vizidor 20mg/ml of dorzolamide product shot
Vizidor 20mg/ml of dorzolamide product shot

Vizidor 20 mg/ml eye drops solution (Preservative Free)

(20mg/ml of dorzolamide)

Composition:

Each ml contains 20 mg of dorzolamide (as dorzolamide hydrochloride)

Indication:

As adjunctive therapy to beta-blockers, as monotherapy in patients unresponsive to beta-blockers or in whom beta- blockers are contraindicated, in the treatment of elevated intra-ocular pressure in ocular hypertension, open-angle glaucoma and pseudoexfoliative glaucoma

Vizidor Duo 20 mg/ml + 5 mg/ml eye drops, solution-Preservative Free product shot
Vizidor Duo 20 mg/ml + 5 mg/ml eye drops, solution-Preservative Free product shot

Vizidor Duo 20 mg/ml + 5 mg/ml eye drops, solution (Preservative Free)

(20mg/ml of dorzolamide + 5 mg/ml of timolol)

Composition:

Each ml contains 20 mg of dorzolamide (as hydrochloride) and 5 mg of timolol (as maleate)

Indication:

Indicated in the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or pseudoexfoliative glaucoma when topical beta-blocker monotherapy is not sufficient.

Reporting side effects:

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search MHRA Yellow Card in the Google Play or Apple App Store Adverse events should also be reported to Bausch + Lomb at: ukmedinformation@bausch.com or call +044 (0) 2087812991

January 2025/VIZ.0017.UK.23